Tumor ‑released lncRNA H19 promotes gefitinib resistance via packaging into exosomes in non‑small cell lung cancer.

In conclusion, H19 promoted gefitinib resistance of NSCLC cells by packaging into exosomes. Therefore, exosomal H19 may be a promising therapeutic target for EGFR+ NSCLC patients. PMID: 30542738 [PubMed - as supplied by publisher]
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research